纳斯达克 · 生物技术 · USD
Daré Bioscience, Inc. (DARE) 股票分析
Daré Bioscience, Inc.(DARE)是在纳斯达克上市的生物技术股票,以美元交易。
最后更新: 2026年10月21日
价格走势
暂无价格数据
悬停查看每日收盘价。虚线表示区间起始价。
DARE 关键统计数据
数据截至2026年10月21日交易
- 开盘价
- $0.68
- 前收盘价
- $0.69
- 当日波动区间
- 0.67–0.71
- 52周波动区间
- 0.67–3.78
- 成交量
- 2.42万
- Beta系数股价相对大盘的波动幅度。1.0与大盘同步,高于1.0波动更大,低于1.0更小。
- 1.01
估值
- 市值
- $1353.23万
- 市盈率
- 亏损
- 市销率市值除以年营业收入。适用于尚未盈利、无法计算市盈率的公司。
- 9.91
- 每股收益(近12个月)过去十二个月归属于每股的利润。
- −0.71
财务(财年)
- 营业收入(财年)
- $103.02万+10,429.36%
- 净利润(财年)
- −$1339.93万
- 流通股数
- 1966.91万
- 一年回报率
- −67.70%
股息与日期
- 财报日期
- 2026年11月12日
- 平均成交量
- 50.59万
仅显示公司披露的指标。 数据由Yahoo Finance通过yfinance提供。每日更新。
关键数据
截至2026年10月21日,DARE收盘价为$0.69,1年回报率为−67.70%。
Daré Bioscience, Inc.(DARE)的市值为$1353.23万。
2025财年,DARE的营业收入为$103.02万。
DARE 历年回报率
Daré Bioscience, Inc.(DARE)10年回报:$10,000变成了多少
- 1年
- $10,000 $3,230
- −67.70%
- 5年
- $10,000 $387
- −96.13%
- 10年
- $10,000 $61
- −99.39%
如果在10年前,即2016年10月21日收盘时,向Daré Bioscience, Inc.(DARE)投资$10,000,按2026年10月21日收盘价计算将变为$61:累计−99.39%,年化−39.97%。基于经拆股和股息调整的收盘价进行的历史测算,未计入费用和税费。
历年回报率根据每日收盘价计算。 不完整年度以浅色显示并标有星号。
| 年份 | 回报率 |
|---|---|
| 2026 (不完整年度) | −64.35% |
| 2025 | −38.14% |
| 2024 | −15.86% |
| 2023 | −62.77% |
| 2022 | −58.50% |
| 2021 | +49.25% |
| 2020 | +63.41% |
| 2019 | +15.33% |
| 2018 | −67.14% |
| 2017 | −69.44% |
| 2016 (不完整年度) | −74.71% |
数据截至2026年10月21日。
DARE 各财年营收与利润
财年截至十二月| 财年 | 营业收入 | 净利润 | 净利率 |
|---|---|---|---|
| 2025 | $103.02万 | −$1339.93万 | −1,300.7% |
| 2024 | $9784.00 | −$405.36万 | −41,430.9% |
| 2023 | $280.79万 | −$3016.14万 | −1,074.2% |
| 2022 | $1000.00万 | −$3094.77万 | −309.5% |
| 财年 | 营业收入 | 毛利 | 营业利润 | 净利润 | 净利率 |
|---|---|---|---|---|---|
| 2025 | $103.02万 | $73.44万 | −$1355.23万 | −$1339.93万 | −1,300.7% |
| 2024 | $9784.00 | — | −$2345.15万 | −$405.36万 | −41,430.9% |
| 2023 | $280.79万 | — | −$3093.99万 | −$3016.14万 | −1,074.2% |
| 2022 | $1000.00万 | — | −$3138.55万 | −$3094.77万 | −309.5% |
为公司报告货币口径的年度公布数据。 数据截至2025年12月31日。
DARE估值与生物技术中位数对比
608只股票的中位数| 指标 | DARE | 生物技术中位数 | 相对中位数 |
|---|---|---|---|
| 市销率 | 9.91 | 13.30 | 低26% |
基于608只披露该指标的生物技术股票的中位数。采用中位数而非平均值,异常值不会扭曲结果。 数据截至2026年10月21日。
最新新闻
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
YahooDaré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
YahooDaré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
YahooDaré Bioscience To Present Clinical Data From A Phase 1 Study Evaluating Sildenafil Cream, 3.6% Investigational Product At The Sexual Medicine Society Of North America Meeting, October 8-11
BenzingaDaré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance
BenzingaDare Bioscience stock rises after receiving HPV treatment patent
Yahoo
全部20篇文章 ↓收起 ↑
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
YahooDaré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies
BenzingaDaré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
YahooDaré Bioscience Announces Publication Of Results From A Phase 1 Clinical Study Evaluating Safety And Systemic Pharmacokinetics Of Topical Sildenafil Cream, 3.6%, In Healthy Adult Men In The Journal Sexual Medicine; At 71 Mg Topical Dose, Mean Maximum Plasma Concentration Of Sildenafil Was ~187-Fold Lower Than Following A 50 Mg Oral Dose
BenzingaDaré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
YahooDaré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
YahooDaré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
SeekingAlphaDare Bioscience Files Prospectus Related To The Resale Of Up To 8,934,345 Shares Of Common Stock By Selling Stockholders
BenzingaDaré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure
BenzingaDaré Bioscience Announces $6M Offering Of 4,379,581 Shares (Or Pre-Funded Warrants To Purchase Shares Of Common Stock In Lieu Thereof) At $1.37/Share
BenzingaDaré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
SeekingAlphaDare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript
BenzingaDare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate
BenzingaDaré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript
SeekingAlpha
新闻由第三方来源提供。不构成投资建议。
分析
数据生成以上所有数字均在每日重新生成时从本页自身的数据中读取。仅供参考,不构成投资建议。 数据截至2026年10月21日。
相关生物技术股票
Vertex Pharmaceuticals Incorporated
$1329.45亿
MRNAModerna, Inc.
$981.36亿
REGNRegeneron Pharmaceuticals, Inc.
$829.48亿
ARGXargenx SE
$559.72亿
ONCBeOne Medicines AG
$439.67亿
RVMDRevolution Medicines, Inc.
$416.41亿
医疗保健热门股票
Eli Lilly and Company
$1.13万亿
JNJJohnson & Johnson
$6212.24亿
ABBVAbbVie Inc.
$5032.75亿
UNHUnitedHealth Group Incorporated
$3742.97亿
MRKMerck & Co., Inc.
$3697.80亿












